Granulocyte Colony Stimulating Factor (G-CSF) to Treat Acute-on-chronic Liver Failure
Status:
Completed
Trial end date:
2020-03-01
Target enrollment:
Participant gender:
Summary
Multicentre, open, randomised, and controlled trial conducted in patients diagnosed with
acute on chronic liver failure (ACLF) who meet inclusion/exclusion criteria.The objective of
GRAFT-trial is to evaluate efficacy and safety of subcutaneously administered granulocyte
colony-stimulating factor (G-CSF) in patients with ACLF. All patients will receive standard
medical care for ACLF according to the guidelines. Patients in the experimental arm
additional receive subcutaneous injections of G-CSF.